Home
University of Bergen
Kimberley Joanne Hatfield's picture

Kimberley Joanne Hatfield

Guest Researcher, Researcher
Department of Clinical Science
  • E-mailkimberley.hatfield@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen

The main research aim is to characterize metabolic phenotypes of human leukemia cells, and investigate how metabolic pathways may be implicated in the development of cancer cells`drug resistance.
Additional research interests include the contribution of the microenvironment in acute myeloid leukemia (AML); in particular how leukemia cells are influenced by stromal cells and chemokines, and how leukemia cells adapt to changes in oxygen levels and nutrient availability.

  • Show author(s) (2022). Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients. Cancers. 21 pages.
  • Show author(s) (2022). NPM1-mutated patient-derived AML cells are more vulnerable to rac1 inhibition. Biomedicines. 16 pages.
  • Show author(s) (2022). MicroRNA serum profiles and chronic graft-versus-host disease. Blood Advances. 5295-5306.
  • Show author(s) (2022). Heterogeneity of patient-derived acute myeloid leukemia cells subjected to SYK in vitro inhibition. International Journal of Molecular Sciences. 21 pages.
  • Show author(s) (2022). Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. Biomolecules.
  • Show author(s) (2021). Effects of the autophagy‐inhibiting agent chloroquine on acute myeloid leukemia cells; characterization of patient heterogeneity. Journal of Personalized Medicine. 1-23.
  • Show author(s) (2020). The PI3K-AKT-MTOR signaling pathway in human acute myeloid leukemia (AML) cells. International Journal of Molecular Sciences. 1-22.
  • Show author(s) (2020). Targeting cellular metabolism in acute myeloid leukemia and the role of patient heterogeneity. Cells. 1-26.
  • Show author(s) (2019). Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. Cells.
  • Show author(s) (2019). Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. Signal Transduction and Targeted Therapy.

More information in national current research information system (CRIStin)

Bergen Research Foundation funded project: Characterization of metabolic phenotypes and signaling pathways in acute myeloid leukemia and their role in anti-leukemia treatment.